Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal

Allergologia et Immunopathologia

Volumn 42, Issue 1, 2014, Pages 3-10

  Vieira, T ^a   de Oliveira, J F ^a   da Graca Castel Branco M ^a  

^a Universidade do Porto   (Portugal)

Author keywords

Asthma control; Omalizumab; Quality of life; Safety; Severe asthma

Indexed keywords

ASTHMA CONTROL; OMALIZUMAB; QUALITY OF LIFE; SAFETY; SEVERE ASTHMA;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PORTUGAL; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893850431     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2012.07.006     Document Type: Article

References (40)

1. Asher M.I., Montefort S., Björkstén B., Lai C.K., Strachan D.P., Weiland S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006, 368:733-743.
2. Covar R.A., Szefler S.J., Zeiger R.S., Sorkness C.A., Moss M., Mauger D.T., et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. J Allergy Clin Immunol 2008, 122:741-747.
3. Spahn J.D., Covar R. Clinical assessment of asthma progression in children and adults. J Allergy Clin Immunol 2008, 121:548-557.
4. Cazzoletti L., Marcon A., Corsico A., Janson C., Jarvis D., Pin I., et al. Asthma severity according to global initiative for asthma and its determinants: an international study. Int Arch Allergy Immunol 2010, 151:70-79.
5. Moy M.L., Israel E., Weiss S.T., Juniper E.F., Dubé L., Drazen J.M. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 2001, 163:924-929.
6. Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012, 21:66-74.
7. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190.
8. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007; 120(5 Suppl.):S94-138.
9. [Online]. http://www.ginasthma.org/Guidelines/guidelines-resources.html.
10. Rodrigo G.J., Neffen H., Castro-Rodriguez J.A. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011, 139:28-35.
11. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
12. Hanania N.A., Alpan O., Hamilos D.L., Condemi J.J., Reyes-Rivera I., Zhu J., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154:573-582.
13. Finn A., Gross G., van Bavel J., Lee T., Windom H., Everhard F., et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003, 111:278-284.
14. Niebauer K., Dewilde S., Fox-Rushby J., Revicki D.A. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006, 96:316-326.
15. Chipps B., Buhl R., Beeh K.M., Fox H., Thomas K., Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006, 22:2201-2208.
16. Cazzola M., Camiciottoli G., Bonavia M., Gulotta C., Ravazzi A., Alessandrini A., et al. Italian real-life experience of omalizumab. Respir Med 2010, 104:1410-1416.
17. Brusselle G., Michils A., Louis R., Dupont L., Van de Maele B., Delobbe A., et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009, 103:1633-1642.
18. Molimard M., Buhl R., Niven R., Le Gros V., Thielen A., Thirlwell J., et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010, 104:1381-1385.
19. Korn S., Thielen A., Seyfried S., Taube C., Kornmann O., Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009, 103:1725-1731.
20. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003, 19:491-498.
21. Winder J.A., Nash K., Brunn J.W. Validation of a life quality (LQ) test for asthma. Ann Allergy Asthma Immunol 2000, 85(6 Pt 1):467-472.
22. Fonseca J.A., Delgado L., Costa-Pereira A., Tavares C., Moreira A., Morete A., et al. Evaluation of the Asthma Life Quality test for the screening and severity assessment of asthma. Allergy 2004, 59:1198-1204.
23. Thomas M., Kay S., Pike J., Williams A., Rosenzweig J.R., Hillyer E.V., et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009, 18:41-49.
24. Roxo J.P., Ponte E.V., Ramos D.C., Pimentel L., D'Oliveira Júnior A., Cruz A.A. Portuguese-language version of the Asthma Control Test. J Bras Pneumol 2010, 36:159-166.
25. Juniper E.F., Guyatt G.H., Epstein R.S., Ferrie P.J., Jaeschke R., Hiller T.K. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992, 47:76-83.
26. Juniper E.F., Guyatt G.H., Willan A., Griffith L.E. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994, 47:81-87.
27. Molimard M., de Blay F., Didier A., Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008, 102:71-76.
28. Braunstahl G.J., Leo J., Thirlwell J., Peachey G., Maykut R. Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Curr Med Res Opin 2011, 27:761-767.
29. Price D. The use of omalizumab in asthma. Prim Care Respir J 2008, 17:62-72.
30. Holgate S., Smith N., Massanari M., Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009, 64:1728-1736.
31. Bai T.R., Vonk J.M., Postma D.S., Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007, 30:452-456.
32. Silkoff P.E., Romero F.A., Gupta N., Townley R.G., Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 2004, 113:e308-e312.
33. Thier S.L., Yu-Isenberg K.S., Leas B.F., Cantrell C.R., DeBussey S., Goldfarb N.I., et al. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care 2008, 17:48-57.
34. Pace E., Ferraro M., Bruno A., Chiappara G., Bousquet J., Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma 2011, 48:387-392.
35. Nopp A., Johansson S.G., Ankerst J., Palmqvist M., Oman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007, 62:1175-1181.
36. Nopp A., Johansson S.G., Adédoyin J., Ankerst J., Palmqvist M., Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010, 65:56-60.
37. Corren J., Casale T.B., Lanier B., Buhl R., Holgate S., Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009, 39:788-797.
38. Cox L., Platts-Mills T.A., Finegold I., Schwartz L.B., Simons F.E., Wallace D.V. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007, 120:1373-1377.
39. Tan R., Corren J. Omalizumab in the treatment of asthma. Expert Rev Respir Med 2011, 5:747-756.
40. Long A.A., Fish J.E., Rahmaoui A., Miller M.K., Bradley M.S., Taki H.N., et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009, 103:212-219.